A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Lately, Pfizer (NYSE: PFE) ...

With volatility begetting opportunity, here are all six stocks I've bought through the first five months of 2025. Image ...

Two drugs. Two strategies. One industry in the middle of a rewiring.

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

A vaccine expert assured Filipinos on Wednesday that all vaccines are safe after the United States Food and Drug ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

During the 2024-2025 academic year, the UConn School of Pharmacy fielded a team that placed sixth out of 70 schools or ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, ...